Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
The optimal treatment of type 2 diabetes is currently uncertain. This article reviews a new class of oral hypoglycaemic agents: dipeptidyl peptidase-IV inhibitors. By potentiating the action of incretins they offer a more 'physiological' control of blood sugar with fewer side effects, and the possibility of ameliorating the decline in beta cell function.